Transcription factors in hematopoietic malignancies

Current Opinion in Genetics and Development

Volumn 17, Issue 1, 2007, Pages 78-83

  Gery, Sigal ^a   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; MIXED LINEAGE LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CHROMOSOME TRANSLOCATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; LEUKEMIA CELL; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; T LYMPHOCYTE;

GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; POINT MUTATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 33846190677     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2006.12.012     Document Type: Review

References (31)

1. Rubnitz J.E., and Look A.T. Molecular basis of leukemogenesis. Curr Opin Hematol 5 (1998) 264-270
2. Lin R.J., Sternsdorf T., Tini M., and Evans R.M. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 20 (2001) 7204-7215
3. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
4. Hellebrekers D.M., Griffioen A.W., and van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta (2006) 10.1016/j.bbcan.2006.07.003
5. Kelly L.M., and Gilliland D.G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3 (2002) 179-198
6. Ansell S.M., and Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 80 (2005) 1087-1097
7. Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R., Vermeesch J.R., Stul M., Dutta B., Boeckx N., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36 (2004) 1084-1089
8. Lazar A., Abruzzo L.V., Pollock R.E., Lee S., and Czerniak B. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med 130 (2006) 1199-1207
9. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648. The authors developed a method, termed cancer outlier profile analysis (COPA), to detect recurrent gene rearrangements in specific cancer types by analyzing microarray data sets. Using this method, they identified two ETS transcription factors as outliers in prostate cancer. Fusions between the ETS genes and TMPRSS2, an androgen-regulated gene, were found in the majority of prostate cancers. This study suggests that recurrent translocations could be found in common epithelial cancers.
10. Huntly B.J., and Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5 (2005) 311-321
11. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442 (2006) 818-822. Leukemia stem cells can maintain the global identity of normal progenitors while activating a subset of genes that are associated with self-renewal and which are normally expressed in haematopoietic stem cells.
12. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., Behre G., Hiddemann W., and Tenen D.G. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet 27 (2001) 263-270. The first report to describe mutations of the tumor suppressor gene C/EBPα in cancer patients.
13. Gombart A.F., Hofmann W.K., Kawano S., Takeuchi S., Krug U., Kwok S.H., Larsen R.J., Asou H., Miller C.W., Hoelzer D., and Koeffler H.P. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias. Blood 99 (2002) 1332-1340
14. Smith M.L., Cavenagh J.D., Lister T.A., and Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351 (2004) 2403-2407. This study suggests that substantial reduction in C/EBPα function, rather than haploinsufficiency, confers a predisposition to AML, and confirms clinical observations that sporadic C/EBPα mutations predict favorable outcome in specific AML subtypes.
15. Wechsler J., Greene M., McDevitt M.A., Anastasi J., Karp J.E., Le Beau M.M., and Crispino J.D. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 (2002) 148-152. The authors suggest a mechanism for leukemia development that involves GATA-1 and increased expression levels of genes on chromosome 21 in Down's syndrome.
16. Hollanda L.M., Lima C.S., Cunha A.F., Albuquerque D.M., Vassallo J., Ozelo M.C., Joazeiro P.P., Saad S.T., and Costa F.F. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38 (2006) 807-812. The first study to indicate that a germline mutation in GATA-1 does not cause leukemia in the absence of cooperating events, such as Down's syndrome.
17. Mueller B.U., Pabst T., Osato M., Asou N., Johansen L.M., Minden M.D., Behre G., Hiddemann W., Ito Y., and Tenen D.G. Heterozygous PU. 1 mutations are associated with acute myeloid leukaemia. Blood 101 (2003) 2074
18. Song W.J., Sullivan M.G., Legare R.D., Hutchings S., Tan X., Kufrin D., Ratajczak J., Resende I.C., Haworth C., Hock R., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23 (1999) 166-175. The authors demonstrate that mutations in CBFA2 are associated with clinical outcome in hematopoietic cells. This study, together with subsequent reports of mutations in C/EBPα, GATA-1 and PU.1, suggests that mutation of transcription factors with key roles in myeloid lineage commitment is a common mechanism implicated in the pathogenesis of human leukemia.
19. Vegesna V., Takeuchi S., Hofmann W.K., Ikezoe T., Tavor S., Krug U., Fermin A.C., Heaney A., Miller C.W., and Koeffler H.P. C/EBP-β, C/EBP-δ, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res 26 (2002) 451-457
20. Rosenbauer F., Koschmieder S., Steidl U., and Tenen D.G. Effect of transcription-factor concentrations on leukemic stem cells. Blood 106 (2005) 1519-1524
21. Pasqualucci L., Neumeister P., Goossens T., Nanjangud G., Chaganti R.S., Kuppers R., and Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412 (2001) 341-346. A novel mechanism, termed aberrant hypermutation, was identified as a major factor contributing to the development of diffuse large B-cell lymphomas. In these tumors the somatic hypermutation process, which normally targets immunoglobulin V (IgV) genes, is dysregulated, causing mutations in multiple genes, including known proto-oncogenes.
22. Weng A.P., Ferrando A.A., Lee W., Morris IV J.P., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., and Aster J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 (2004) 269-271. The authors discovered novel activating mutations in NOTCH1 in more than 50% of T-cell acute lymphoblastic leukemias, indicating that Notch1 has an important role in the development of this disease.
23. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102 (2005) 13944-13949. This study suggests that miR-15 and miR-16 inhibit expression of the BCL2 oncogene.
24. Massaad C.A., Portier B.P., and Taglialatela G. Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2. J Biol Chem 279 (2004) 54470-54478
25. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., and Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 435 (2005) 828-833. A cluster of miRNAs can enhance c-Myc oncogenic activities, implicating miRNAs as potential human oncogenes.
26. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., and Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435 (2005) 839-843. c-Myc upregulates a cluster of miRNAs that, in turn, downregulate the c-Myc target gene E2F1. This enables tightly coordinated expression of E2F1, a transcription factor with vital roles in cell cycle regulation.
27. Dews M., Homayouni A., Yu D., Murphy D., Sevignani C., Wentzel E., Furth E.E., Lee W.M., Enders G.H., Mendell J.T., and Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38 (2006) 1060-1065. This study provides the first demonstration that an miRNA cluster, activated by c-Myc, affects non-cell-autonomous processes such as tumor neovascularization.
28. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., Iorio M.V., Visone R., Sever N.I., Fabbri M., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353 (2005) 1793-1801. A unique microRNA signature was found to be associated with prognostic factors and disease progression in chronic lymphocytic leukemia. This is the first study to show an association between dysregulation of miRNAs and human cancer.
29. Esquela-Kerscher A., and Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6 (2006) 259-269
30. Conaway R.C., Brower C.S., and Conaway J.W. Emerging roles of ubiquitin in transcription regulation. Science 296 (2002) 1254-1258
31. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617. Bortezomib, a proteasome inhibitor, is active in patients with relapsed multiple myelomas that are refractory to conventional chemotherapy.